IDH1 and central nervous system cancer: However, CTRW_α exhibited diminished diagnostic efficacy, particularly reduced sensitivity (using IDH-mutant as positive and wildtype as negative labels), in gliomas demonstrating contrast enhancement, cystic/necrosis changes, or peritumoral edema.